

# Clinical trials of SU

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>sulfinpyrazone vs control</b>			
Dutch sulphinpyrazone , 1986 n=50/50 follow-up: 21d	-	-	Parallel groups
<b>supersaturated oxygen vs control</b>			
AMIHOT II , 2000 [NCT00175058] n=222/79 follow-up:	90-minute intracoronary supersaturated oxygen (SSO(2)) infusion in the left anterior descending artery infarct territory versus control	patients with anterior ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention within 6 hours of symptom onset	
AMIHOT , 2007 n=NA follow-up:	hyperoxemic reperfusion for 90 min using intracoronary aqueous oxygen versus normoxemic blood autoreperfusion	patients with acute anterior or large inferior AMI undergoing primary or rescue PCI (<24 h from symptom onset) and successful PCI	
<b>sulfinpyrazone vs placebo</b>			
Wilcox , 1980 n=49/49 follow-up: 10d	Sulphinpyrazone 200 mg four times daily versus placebo	patients with acute myocardial infarction	Parallel groups
Louvain sulphinpyrazone , 1983 n=15/14 follow-up: 7d	sulphinpyrazone, 4 x 200 mg daily for 7 days versus placebo	recent myocardial infarction	Parallel groups double blind

More details and results :

- antiplatelets drug for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q390>
- oxygen therapy for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q429>

## References

### Dutch sulphinyprazone, 1986:

Funke Kpper AJ, Verheugt FWA, Jaarsma W, Roos JP.age/pj Funke Kpper AJ, Verheugt FWA, Jaarsma W, Roos JP. Failure of sulphinyprazone to prevent left ventricular thrombosis in patients with AMI treated with oral anticoagulants Proceedings of X World Congress of Cardiology. Washington: 1986:419 (Abstract 2414)atio

### AMIHOT II , 2000:

Haude M. AMIHOT-II: A prospective, randomized evaluation of supersaturated oxygen therapy after percutaneous coronary intervention in acute anterior myocardial infarction Herz 2007;32 (8):669

Stone GW, Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, Lansky AJ, Krucoff MW, Fahy M, Boscardin WJ Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv 2009;2:366-75 [20031745] 10.1161/CIRCINTERVENTIONS.108.840066

### AMIHOT, 2007:

O'Neill WW, Martin JL, Dixon SR, Bartorelli AL, Trabattoni D, Oemrawsingh PV, Atsma DE, Chang M, Marquardt W, Oh JK, Krucoff MW, Gibbons RJ, Spears JR Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J Am Coll Cardiol 2007;50:397-405 [17662390] 10.1016/j.jacc.2007.01.099

Stone GW, Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, Lansky AJ, Krucoff MW, Fahy M, Boscardin WJ Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv 2009;2:366-75 [20031745] 10.1161/CIRCINTERVENTIONS.108.840066

### Wilcox, 1980:

Wilcox RG, Richardson D, Hampton JR, Mitchell JR, Banks DC Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function. Br Med J 1980;281:531-4 [7000264]

### Louvain sulphinyprazone, 1983:

Lijnen P, Boelaert J, van Eeghem P, Daneels R, Schurgers M, de Jaegere P, van der Stichele E, Vincke J, Fagard R, Verschueren LJ, Amery A Decrease in renal function due to sulphinyprazone treatment early after myocardial infarction. Clin Nephrol 1983;19:143-6 [6340878]

## 2 post stroke

Trial	Treatments	Patients	Trials design and methods
<b>Device for PFO closure vs medical treatment</b>			
<b>CLOSE</b> <i>ongoing</i> [NCT00562289] n=NA follow-up:	Devices for PFO closure versus aspirin	-	Parallel groups

continued...

Trial	Treatments	Patients	Trials design and methods
<b>CryptoCard</b> <i>ongoing</i> [NCT01018355] n=NA follow-up:	Device closure of PFO followed by medical treatment versus antiplatelet therapy	elderly patients above 50 years of age with a patent foramen ovale and a history of cryptogenic stroke or TIA	open Denmark

More details and results :

- foramen ovale closure for post stroke in all type of patients at <http://www.trialresultscenter.org/go-Q430>

## References

### CLOSE, :

ongoing trial NCT00562289

### CryptoCard, :

ongoing trial NCT01018355

## 3 post myocardial infarction

33

Trial	Treatments	Patients	Trials design and methods
<b>succinobucol vs placebo</b>			
<b>ARISE, 2007</b> [NCT00066898] n=3078/3066 follow-up: 24 months mean	succinobucol (300 mg/day) versus placebo	high-risk patients with recent acute coronary syndrome	Parallel groups Double blind canada, US, UK, South Africa

More details and results :

- antioxydants for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q424>

## References

### ARISE, 2007:

Tardif American College of Cardiology Annual Scientific Session, New Orleans, LA, March 2007 [0]

Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;371:1761-8 [[18502300](#)] [10.1016/S0140-6736\(08\)60763-1](https://doi.org/10.1016/S0140-6736(08)60763-1)

## 4 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>partial ileum bypass surgery vs no surgery</b>			
<b>POSCH , 1990</b> [NCT00000490] n=421/417 follow-up: 9.7 years	partial ileum bypass surgery versus no surgery	survivors to a first myocardial infarction	Parallel groups open
<b>rosuvastatin vs placebo</b>			
<b>AURORA , 2009</b> n=1391/1385 follow-up: 3.2 y mean (max 5.6y)	rosuvastatin 10 mg daily versus placebo	in patients with end-stage renal disease on hemodialysis	Parallel groups double blind
<b>JUPITER (elderly sub group) , 2009</b> n=5695 follow-up: double-blind	rosuvastatin 20mg daily versus placebo	healthy individuals aged $\geq 70$ years with normal LDL cholesterols but with CRP levels $\geq 2.0$ mg/dL	Parallel groups double blind
<b>ASTRONOMER , 2010</b> [ISRCTN 32424163] n=134/135 follow-up: 3.5 y	rosuvastatin 40 mg daily versus placebo	asymptomatic patients with mild to moderate aortic stenosis and no clinical indications for cholesterol lowering	Parallel groups double blind
<b>HOPE 3 , 2016</b> [NCT00468923] n=6361/6344 follow-up: 5.6 years	rosuvastatin 10 mg per day versus placebo	subjects who did not have cardiovascular disease and were at intermediate risk	Factorial plan double-blind 21 countries
<b>CORONA , 2007</b> [NCT00206310] n=2514/2497 follow-up: 32.9 months median	rosuvastatin 10mg/d versus placebo	patients at least 60 years of age with NYHA class II, III, or IV ischemic, systolic heart failure	Parallel groups double blind
<b>Krum , 2007</b> n=40/46 follow-up: 6 months	rosuvastatine 40mg/d versus placebo	patients with systolic (LVEF $<40\%$ ) CHF of ischemic or nonischemic etiology	Parallel groups double blind Australia
<b>GISSI-HF rosuvastatine , 2008</b> [NCT00336336] n=2314/2317 follow-up: 3.9y median (IQR 3-4.4)	low-dose rosuvastatin 10 mg daily versus placebo	Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterol-lowering therapy	Parallel groups double blind Italy

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>JUPITER , 2008</b> [NCT00239681] n=8901/8901 follow-up: median 1.9 year	rosuvastatin 20 mg daily versus placebo	apparently healthy individuals with low LDL-cholesterol levels of less than 130 mg per deciliter but elevated C-reactive-protein (high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher)	Parallel groups double blind 26 countries
<b>METEOR , 2007</b> [NCT00225589] n=702/282 follow-up:	rosuvastatin 40mg daily versus placebo	individuals, with either age (mean, 57 years) as the only coronary heart disease risk factor or a 10-year Framingham risk score of less than 10% , modest CIMT thickening (1.2-<3.5 mm), and elevated LDL cholesterol	Parallel groups double-blind USA, Europe
<b>JUPITER (women subgroup) , 2008</b> n=3426/3375 follow-up: 1.9 y	Rosuvastatin 20 mg daily versus placebo	apparently healthy men and women with low-density lipoprotein cholesterol levels of less than 130 mg/dL and high-sensitivity C-reactive protein levels of 2.0 mg/L or higher - subgroup of women	Parallel groups double-blind 26 countries
<b>succinobucol vs placebo</b>			
<b>ARISE , 2008</b> [NCT00066898] n=3078/3066 follow-up: 24 mo (range 12-36 mo)	succinobucol 300 mg once daily versus placebo	patients with recent (14-365 days) acute coronary syndromes already managed with conventional treatments	Parallel groups double blind Canada, US, UK, South Africa
<b>sulfinyrazone vs placebo</b>			
<b>Dutch , 1980 unpublished</b> n=30/31 follow-up: 32 months	-	-	Parallel groups
<b>suloctidil vs placebo</b>			
<b>Adriaensen , 1976</b> n=15/15 follow-up: 2 months	Suloctidil 200 mg / j versus Placebo	patients suffering from intermittent claudication ( stade II)	Parallel groups double blind
<b>Verhaeghe , 1981</b> n=NA follow-up: 6 months	Suloctidil 200 mg / j versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
<b>Jones , 1982</b> n=18/22 follow-up: 6 months	Suloctidil 300 mg / j versus Placebo	patients suffering from intermittent claudication (stade II)	Parallel groups double blind

continued...

Trial	Treatments	Patients	Trials design and methods
Holm , 1984 n=20/20 follow-up: 2.75 y	Suloctidil 300 mg / j versus Placebo	AOMI stade II	Parallel groups double blind
<b>Super EPA vs placebo</b>			
Reis , 1991 n=146/72 follow-up: 6 months	Super EPA capsules 12x1 g/d (7.0g EPA + DHA + a-lin) ORPromega capsules 12x1 g/d (6.0g EPA + DHA + a-lin) versus placebo (olive oil capsules, 12x1 g/d)	people undergoing angioplasty	Parallel groups double blind US
<b>Rosuvastatin vs control</b>			
ASTEROID <i>ongoing</i> n=NA follow-up:	-	-	

More details and results :

- cholesterol lowering intervention for cardiovascular prevention in elderly at <http://www.trialresultscenter.org/go-Q7>
- cholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation at <http://www.trialresultscenter.org/go-Q11>
- cholesterol lowering intervention for cardiovascular prevention in patients with prior MI or with CHD at <http://www.trialresultscenter.org/go-Q12>
- omega-3 fatty acids for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q121>
- omega-3 fatty acids for cardiovascular prevention in patients at high risk at <http://www.trialresultscenter.org/go-Q123>
- antioxydants for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q131>
- cholesterol lowering intervention for cardiovascular prevention in patient with related disease at <http://www.trialresultscenter.org/go-Q137>
- cholesterol lowering intervention for cardiovascular prevention in all chronical situations at <http://www.trialresultscenter.org/go-Q154>
- antiplatelets drug for cardiovascular prevention in diabetic patients at <http://www.trialresultscenter.org/go-Q220>
- cholesterol lowering intervention for cardiovascular prevention in primary prevention at <http://www.trialresultscenter.org/go-Q241>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>

- cholesterol lowering intervention for cardiovascular prevention in patients with renal insufficiency (on hemodialysis or transplant) at <http://www.trialresultscenter.org/go-Q284>
- cholesterol lowering intervention for cardiovascular prevention in women at <http://www.trialresultscenter.org/go-Q435>
- statins for cardiovascular prevention in primary prevention at <http://www.trialresultscenter.org/go-Q688>
- statins for cardiovascular prevention in diabetic patients at <http://www.trialresultscenter.org/go-Q694>

## References

### **POSCH, 1990:**

Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med 1990;323:946-55 [2205799]

Buchwald H, Rudser KD, Williams SE, Michalek VN, Vagasky J, Connett JE Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg 2010;251:1034-40 [20485136] 10.1097/SLA.0b013e3181deb4d0

### **AURORA, 2009:**

Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 2009;360:1395-407. [19332456]

Fellstrm BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grnhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Sleymanlar G, Tsakiris D, Tesar V Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407 [19332456]

### **JUPITER (elderly sub group), 2009:**

Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152:488-96, W174 [20404379] 10.1059/0003-4819-152-8-201004200-00005

### **ASTRONOMER, 2010:**

Chan KL, Teo K, Dumesnil JG, Ni A, Tam J Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis. Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial. Circulation 2010 Jan 4;: [20048204]

### **HOPE 3, 2016:**

Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusuf K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Va Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016 Apr 2;: [27040132] 10.1056/NEJMoa1600176

### **CORONA, 2007:**

Kjekshus J, Apetrei E, Barrios V, Bhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jnosi A, Kamensk G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberg Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61 [17984166]

**Krum, 2007:**

Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. *J Card Fail* 2007;13:1-7 [[17338996](#)]

**GISSI-HF rosuvastatine, 2008:**

Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. *Eur J Heart Fail* 2004 Aug;6:635-41 [[15302013](#)]

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;372:1231-9 [[18757089](#)]

**JUPITER, 2008:**

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. *N Engl J Med* 2008 Nov 9; [[18997196](#)]

**METEOR, 2007:**

Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. *JAMA* 2007 Mar 28;297:1344-53 [[17384434](#)]

**JUPITER (women subgroup) , 2008:**

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359:2195-207 [[18997196](#)]  
[10.1056/NEJMoa0807646](#)

**ARISE, 2008:**

Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;371:1761-8 [[18502300](#)]

**Dutch, 1980:**

unpublished

Pannebakker M, Jonker JJC, Den Ottolander GJH. Proceedings of VI International Congress of Mediterranean League Against Thrombosis 1980:Abstract 167

**Adriaensen, 1976:**

Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo. Adriaensen H *Curr Med Res Opin* 1976;4:395-401 [[793778](#)]

**Verhaeghe, 1981:**

Controlled trial of suloctidil in intermittent claudication. Verhaeghe R, Van Hoof A, Beyens G *J Cardiovasc Pharmacol* 1981 Mar-Apr;3:279-86 [[6166799](#)]

**Jones, 1982:**

A double-blind trial of suloctidil v. placebo in intermittent claudication. Jones NA, De Haas H, Zahavi J, Kakkar VV *Br J Surg* 1982 Jan;69:38-40 [[6274471](#)]

**Holm, 1984:**

Intermittent claudication: Suloctidil v.s. placebo treatment. Holm J, Lindblad L, Schersten T, Suurkula M *Vasa* 1984;13:175-8 [[6331019](#)]

**Reis, 1991:**



Reis GJ, Boucher TM, Sipperly ME, Silverman DI, McCabe CH, Baim DS, Sacks FM, Grossman W, Pasternak RC Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 1989 Jul 22;2:177-81 [2568519]

### ASTEROID, 0:

ongoing trial

## 5 stable angina

Trial	Treatments	Patients	Trials design and methods
<b>CABG+surgical ventricular reconstruction vs CABG</b>			
<b>STICH (ventricular reconstruction) , 2009</b> [NCT00023595] n=501/499 follow-up: 48 months	CABG with surgical ventricular reconstruction versus CABG	patients with anterior-apical regional left ventricular dysfunction	Parallel groups open

More details and results :

- myocardial revascularization for stable angina in all type of patient at <http://www.trialresultscenter.org/go-Q25>

## References

### STICH (ventricular reconstruction), 2009:

Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009 Apr 23;360:1705-17 [19329820] 10.1056/NEJMoa0900559

Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JL STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol 2010;56:490-8 [20670760] 10.1016/j.jacc.2009.11.102

## 6 hypertension

Trial	Treatments	Patients	Trials design and methods
<b>more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie</b>			
<b>PAST-BP , 2015</b> n=NA	-	-	
<b>Wei , 2013</b> n=NA follow-up: 4 years (mean)	BP <=140/90 mm Hg versus BP <=150/90 mm Hg	Chinese hypertensive patients older than 70 years	Parallel groups China

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>SPS3 , 2013</b> [NCT00059306.] n=NA follow-up:	less than 130 mm Hg versus 130-149 mm Hg	patients lived in North America, Latin America, and Spain and had recent, MRI-defined symptomatic lacunar infarctions	Parallel groups open-label
<b>HOMED-BP , 2012</b> n=NA follow-up: 5.3 years (median)	tight control (<125/<80 mm Hg (TC)) of HBP versus usual control (125-134/80-84 mm Hg (UC))	with an untreated systolic/diastolic HBP of 135-179/85-119 mm Hg	Parallel groups
<b>VANLISH , 2010</b> n=NA follow-up: 3.07 years (median)	strict blood pressure control (<140 mm Hg) versus moderate blood pressure control (>or =140 mm Hg to <150 mm Hg)	patients aged 70 to 84 years with isolated systolic hypertension (sitting blood pressure 160 to 199 mm Hg)	Parallel groups open-label
<b>JATOS , 2008</b> n=2212/2206 follow-up:	strict treatment to maintain systolic blood pressure below 140 mmHg versus mild treatment to maintain systolic blood pressure below 160 but at or above 140 mmHg	elderly hypertensive patients with essential hypertension (65-85 years old, with a pretreatment systolic blood pressure of above 160 mmHg)	Parallel groups open-label
<b>UKPDS-HDS , 1998</b> n=758/390 follow-up: 8.4 years	blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker atenolol as main treatment) versus less tight control aiming at a blood pressure of <180/105 mm Hg	patients with type 2 diabetes	Parallel groups open-label UK
<b>SPRINT , 2015</b> [NCT01206062] n=4678/4683 follow-up:	target of 120 mm Hg versus target of 140 mm Hg	high-risk hypertensive adults 50 years of age and older with one additional cardiovascular risk factor or preexisting kidney disease	Parallel groups open
<b>Cardio-Sis , 2009</b> [NCT00421863] n=558/553 follow-up: 2 years	tighter control of systolic BP with a goal of <130 mm Hg versus usual control, with a goal of <140 mm Hg	nondiabetic patients with hypertension and with SBP of 150 mm Hg or higher confirmed at two different times	Parallel groups open Italy
<b>AASK , 2002</b> n=540/554 follow-up: (range 3-6.4y)	arterial pressure goal of 92 mm Hg or lower versus usual mean arterial pressure goal of 102 to 107 mm Hg/pj	African-Americans, with diastolic blood pressure higher than 94mmHg and a glomerular filtration rate between 20 and 65 ml/min per 1.73 m <sup>2</sup>	Parallel groups open USA

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>ABCD target (H) , 2000</b> n=237/233 follow-up: 5 year	intensive treatment with a diastolic blood pressure goal of 75 mmHg versus moderate treatment with a diastolic blood pressure goal of 80-89 mmHg	diabetes patients with DBP $\geq$ 90 mmHg	Parallel groups open
<b>ABCD target (N) , 2002</b> n=237/243 follow-up:	intensive treatment (diastolic blood pressure decrease of 10 mmHg below baseline DBP) versus moderate treatment (diastolic blood pressure goal of 80-89 mmHg)	diabetes patients with diastolic blood pressure between 80 and 89mmHg	Parallel groups open
<b>HOT , 1994</b> n=12526/6264 follow-up: 3.8 y	less or equal than 85 mmHg, or less or equal than 80 mmHg versus less or equal than 90 mmHg	patients with diastolic blood pressure between 100 mmHg and 115 mmHg	Factorial plan open 26 countries
<b>REIN-2 , 2005</b> n=169/169 follow-up: 36 months	intensified (systolic/diastolic $<$ 130/80 mm Hg) blood-pressure control versus conventional (diastolic $<$ 90 mm Hg) blood-pressure control	patients with non-diabetic proteinuric nephropathies receiving background treatment with the ACE inhibitor ramipril	open
<b>MDRD , 1994</b> n=840 follow-up: 2.2 y	low target blood pressure (mean arterial pressure $<$ 92 mm Hg) versus usual target blood pressure (mean arterial pressure $<$ 107 mm Hg)	patients with predominantly nondiabetic kidney disease and a glomerular filtration rate of 13 to 55 mL/min per 1.73 m <sup>2</sup>	open
<b>Toto , 1995</b> n=42/35 follow-up:	strict blood pressure control (DBP 65 to 80 mm Hg) versus usual blood pressure control (DBP 85 to 95 mm Hg)	non-diabetic patients (age 25 to 73) with long-standing hypertension (DBP $\geq$ 95 mm Hg), chronic renal insufficiency (GFR $\leq$ 70 mL/min/1.73 m <sup>2</sup> ) and a normal urine sediment	open
<b>ACCORD blood pressure , 2008</b> [NCT00000620] n=2362/2371 follow-up: 4.7y	intensive therapy, targeting a systolic pressure of less than 120 mm Hg versus standard therapy, targeting a systolic pressure of less than 140 mm Hg	patients with a median glycated hemoglobin level of 8.1% at high risk for cardiovascular events	Factorial plan open USA, Canada
<b>ESH-CHL-SHOT</b> <i>ongoing</i> [NCT01563731] n=NA	-	-	

More details and results :

- anti hypertensive agents for hypertension in diabetic patients at <http://www.trialresultscenter.org/go-Q10>

- intensive blood pressure control for hypertension in all type of patients at <http://www.trialresultscenter.org/go-Q336>
- intensive blood pressure control for hypertension in diabetic patients at <http://www.trialresultscenter.org/go-Q343>
- intensive blood pressure control for hypertension in non diabetic patients at <http://www.trialresultscenter.org/go-Q344>
- intensive blood pressure control for hypertension in patients with chronic kidney disease at <http://www.trialresultscenter.org/go-Q495>

## References

### **PAST-BP, 2015:**

#### **Wei, 2013:**

Wei Y, Jin Z, Shen G, Zhao X, Yang W, Zhong Y, Wang J Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. *J Clin Hypertens (Greenwich)* 2013;15:420-7 [23730991] [10.1111/jch.12094](https://doi.org/10.1111/jch.12094)

#### **SPS3, 2013:**

Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. *Lancet* 2013;382:507-15 [23726159] [10.1016/S0140-6736\(13\)60852-1](https://doi.org/10.1016/S0140-6736(13)60852-1)

#### **HOMED-BP, 2012:**

Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, Thijs L, Staessen JA, Imai Y Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. *Hypertens Res* 2012;35:1102-10 [22895063] [10.1038/hr.2012.125](https://doi.org/10.1038/hr.2012.125)

#### **VANLISH, 2010:**

Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. *Hypertension* 2010;56:196-202 [20530299] [10.1161/HYPERTENSIONAHA.109.146035](https://doi.org/10.1161/HYPERTENSIONAHA.109.146035)

#### **JATOS, 2008:**

Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). *Hypertens Res* 2008;31:2115-27 [19139601] [10.1291/hypres.31.2115](https://doi.org/10.1291/hypres.31.2115)

#### **UKPDS-HDS, 1998:**

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998;317:703-13 [9732337]

#### **SPRINT, 2015:**

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med* 2015 Nov 9; [26551272] [10.1056/NEJMoa1511939](https://doi.org/10.1056/NEJMoa1511939)

#### **Cardio-Sis, 2009:**

Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. *Lancet* 2009;374:525-33 [19683638]

#### **AASK, 2002:**

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA* 2002;288:2421-31 [[12435255](#)]

**ABCD target (H) , 2000:**

Estacio RO, Jeffers BW, Gifford N, Schrier RW Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. *Diabetes Care* 2000;23 Suppl 2:B54-64 [[10860192](#)]

**ABCD target (N) , 2002:**

Schrier RW, Estacio RO, Esler A, Mehler P Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kidney Int* 2002;61:1086-97 [[11849464](#)] [10.1046/j.1523-1755.2002.00213.x](#)

**HOT, 1994:**

Hansson L, Zanchetti A, Carruthers SG, Dahlf B, Elmfeldt D, Julius S, Mnaad J, Rahm KH, Wedel H, Westerling S Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998;351:1755-62 [[9635947](#)]

Hansson L, Zanchetti A The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. *Blood Press* 1997;6:313-7 [[9360003](#)]

Hansson L, Zanchetti A The Hypertension Optimal Treatment (HOT) Study-patient characteristics: randomization, risk profiles, and early blood pressure results. *Blood Press* 1994;3:322-7 [[7866597](#)]

Zanchetti A, Hansson L, Dahlf B, Elmfeldt D, Kjeldsen S, Kolloch R, Laroche P, McInnes GT, Mallion JM, Ruilope L, Wedel H Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. *J Hypertens* 2001;19:1149-59 [[11403365](#)]

**REIN-2, 2005:**

Ruggenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardi D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet* 2005;365:939-46 [[15766995](#)] [10.1016/S0140-6736\(05\)71082-5](#)

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998;317:703-13 [[9732337](#)]

**MDRD, 1994:**

Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med* 1994;330:877-84 [[8114857](#)]

Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. *Hypertension* 1997;29:641-50 [[9040451](#)]

Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med* 1995;123:754-62 [[7574193](#)]

Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. *Ann Intern Med* 2005;142:342-51 [[15738453](#)]

**Toto, 1995:**

Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis.

Kidney Int 1995;48:851-9 [7474675]

### ACCORD blood pressure, 2008:

Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59 [18539917] 10.1056/NEJMoa0802743

Cushman WC, Grimm RH Jr, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:44i-55i [17599425] 10.1016/j.amjcard.2007.03.005

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 2010 Mar 14;: [20228401] 10.1056/NEJMoa1001286

### ESH-CHL-SHOT, :

ongoing trial NCT01563731

## 7 heart failure

Trial	Treatments	Patients	Trials design and methods
<b>rosuvastatin vs placebo</b>			
<b>CORONA , 2007</b> [NCT00206310] n=2514/2497 follow-up: 32.9 months median	rosuvastatin 10mg/d versus placebo	patients at least 60 years of age with NYHA class II, III, or IV ischemic, systolic heart failure	Parallel groups double blind
<b>Krum , 2007</b> n=40/46 follow-up: 6 months	rosuvastatine 40mg/d versus placebo	patients with systolic (LVEF<40% ) CHF of ischemic or nonischemic etiology	Parallel groups double blind Australia
<b>GISSI-HF rosuvastatine , 2008</b> [NCT00336336] n=2314/2317 follow-up: 3.9y median (IQR 3-4.4)	low-dose rosuvastatin 10 mg daily versus placebo	Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterollowering therapy	Parallel groups double blind Italy

More details and results :

- cholesterol lowering intervention for heart failure in elderly at <http://www.trialresultscenter.org/go-Q77>
- cholesterol lowering intervention for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q176>
- statins for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q696>

## References

### CORONA, 2007:

Kjekshus J, Apetrei E, Barrios V, Bhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jnosi A, Kamensk G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberg Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;357:2248-61 [17984166]

### Krum, 2007:

Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. *J Card Fail* 2007;13:1-7 [17338996]

### GISSI-HF rosuvastatine, 2008:

Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. *Eur J Heart Fail* 2004 Aug;6:635-41 [15302013]

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;372:1231-9 [18757089]

## 8 atrial fibrillation

15

Trial	Treatments	Patients	Trials design and methods
<b>rosuvastatin vs placebo</b>			
GISSI HF (subgroup and ancillary study) , 2009 [NCT00336336] n=1855/1835 follow-up: 3.7y (median)	rosuvastatin 10mg daily versus placebo	patients with chronic heart failure who were not in AF at study entry	Factorial plan double-blind Italy

More details and results :

- prevention for atrial fibrillation in patients without history of AF (primary prevention) at <http://www.trialresultscenter.org/go-Q331>

## References

### GISSI HF (subgroup and ancillary study), 2009:

Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G, Tavazzi L Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. *Eur Heart J* 2009 Oct;30:2327-36 [19717850]

## 9 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
<b>sulfinpyrazone vs control</b>			
Dutch sulphinpyrazone , 1986 n=50/50 follow-up: 21d	-	-	Parallel groups
<b>supersaturated oxygen vs control</b>			
AMIHOT II , 2000 [NCT00175058] n=222/79 follow-up:	90-minute intracoronary supersaturated oxygen (SSO(2)) infusion in the left anterior descending artery infarct territory versus control	patients with anterior ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention within 6 hours of symptom onset	
AMIHOT , 2007 n=NA follow-up:	hyperoxemic reperfusion for 90 min using intracoronary aqueous oxygen versus normoxemic blood autoreperfusion	patients with acute anterior or large inferior AMI undergoing primary or rescue PCI (<24 h from symptom onset) and successful PCI	
<b>aspirin + sulfinpyrazone vs placebo</b>			
Canadian (Aspirin + sulfinpyrazone) , 1985 n=416/139 follow-up: 18m	Aspirin 1300mg/d + sulfinpyrazone 800mg/d versus placebo	patients with unstable angina	double blind
<b>sulfinpyrazone vs placebo</b>			
Canadian (sulfinpyrazone alone) , 1985 n=NA follow-up: 18m	sulfinpyrazone 800mg/d versus placebo	patients with unstable angina	double blind
Wilcox , 1980 n=49/49 follow-up: 10d	Sulphinpyrazone 200 mg four times daily versus placebo	patients with acute myocardial infarction	Parallel groups
Louvain sulphinpyrazone , 1983 n=15/14 follow-up: 7d	sulphinpyrazone, 4 x 200 mg daily for 7 days versus placebo	recent myocardial infarction	Parallel groups double blind
<b>prasugrel vs clopidogrel</b>			

continued...



<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>JUMBO-TIMI 26 , 2005</b> n=650/254 follow-up: 30 days	Prasugrel 3 doses versus clopidogrel 300mg loading dose followed by 75 mg daily)	patients undergoing elective or urgent percutaneous coronary intervention	Parallel groups double blind
<b>TRILOGY ACS (overall population) , 2012</b> [NCT00699998] n=4663/4663 follow-up: 17 months (median)	prasugrel 10 mg daily versus clopidogrel 75 mg daily	patients with acute coronary syndromes selected for a final treatment strategy of medical management without revascularization within 10 days after the index event	Parallel groups double-blind 52 countries
<b>TRITON-TIMI 38 , 2007</b> [NCT00097591] n=6813/6795 follow-up:	prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months versus clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months	patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention	Parallel groups double blind 30 countries
<b>ACAPULCO</b> <i>ongoing</i> n=NA	-	-	
<b>surgery vs medical treatment</b>			
<b>VA cooperative , 1987</b> n=231/237 follow-up: 2 years (5,10 years)	coronary-artery bypass surgery plus medical therapy versus medical therapy alone	men with unstable angina pectoris	Parallel groups open US

More details and results :

- myocardial revascularization for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q22>
- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antiplatelets drug for acute coronary syndrome in ACS (excluding AMI) at <http://www.trialresultscenter.org/go-Q169>
- antiplatelets drug for acute coronary syndrome in patients with scheduled percutaneous coronary intervention at <http://www.trialresultscenter.org/go-Q170>
- antiplatelets drug for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q346>
- oxygen therapy for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q428>
- New P2Y12 Inhibitors for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q455>

- antiplatelets drug for acute coronary syndrome in STEMI patients at <http://www.trialresultscenter.org/go-Q564>
- antiplatelets drug for acute coronary syndrome in patients not initially planned for PCI at <http://www.trialresultscenter.org/go-Q652>

## References

### **Dutch sulphinpyrazone, 1986:**

Funke Kpper AJ, Verheugt FWA, Jaarsma W, Roos JP. Failure of sulphinpyrazone to prevent left ventricular thrombosis in patients with AMI treated with oral anticoagulants Proceedings of X World Congress of Cardiology. Washington: 1986:419 (Abstract 2414)

### **AMIHOT II , 2000:**

Haude M. AMIHOT-II: A prospective, randomized evaluation of supersaturated oxygen therapy after percutaneous coronary intervention in acute anterior myocardial infarction Herz 2007;32 (8):669

Stone GW, Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, Lansky AJ, Krucoff MW, Fahy M, Boscardin WJ Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv 2009;2:366-75 [20031745] [10.1161/CIRCINTERVENTIONS.108.840066](https://doi.org/10.1161/CIRCINTERVENTIONS.108.840066)

### **AMIHOT, 2007:**

O'Neill WW, Martin JL, Dixon SR, Bartorelli AL, Trabattoni D, Oemrawsingh PV, Atsma DE, Chang M, Marquardt W, Oh JK, Krucoff MW, Gibbons RJ, Spears JR Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J Am Coll Cardiol 2007;50:397-405 [17662390] [10.1016/j.jacc.2007.01.099](https://doi.org/10.1016/j.jacc.2007.01.099)

Stone GW, Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, Lansky AJ, Krucoff MW, Fahy M, Boscardin WJ Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv 2009;2:366-75 [20031745] [10.1161/CIRCINTERVENTIONS.108.840066](https://doi.org/10.1161/CIRCINTERVENTIONS.108.840066)

### **Canadian (Aspirin + sulfinpyrazone), 1985:**

Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75 [3903504]

### **Canadian (sulfinpyrazone alone), 1985:**

Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG N Engl J Med 1985;313:1369-75 [3903504]

### **Wilcox, 1980:**

Wilcox RG, Richardson D, Hampton JR, Mitchell JR, Banks DC Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function. Br Med J 1980;281:531-4 [7000264]

### **Louvain sulphinpyrazone, 1983:**

Lijnen P, Boelaert J, van Eeghem P, Daneels R, Schurgers M, de Jaegere P, van der Stichele E, Vincke J, Fagard R, Verschueren LJ, Amery A Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction. Clin Nephrol 1983;19:143-6 [6340878]

### **JUMBO-TIMI 26, 2005:**

Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint

Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. *Circulation* 2005 Jun 28;111:3366-73 [15967851]

### **TRILOGY ACS (overall population), 2012:**

Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. *Am Heart J* 2010;160:16-22.e1 [20598967] 10.1016/j.ahj.2010.04.022

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. *N Engl J Med* 2012 Aug 25;: [22920930] 10.1056/NEJMoa1205512

### **TRITON-TIMI 38, 2007:**

Antman EM, Wiviott SD, Murphy SA, Voitek J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. *J Am Coll Cardiol* 2008 May 27;51:2028-33 [18498956]

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007;357:2001-15 [17982182]

### **ACAPULCO, :**

ongoing trial

Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthlmy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. *Thromb Haemost* 2010;103:213-23 [20062936] 10.1160/TH09-07-0482

### **VA cooperative, 1987:**

Luchi RJ, Scott SM, Deupree RH Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. *N Engl J Med* 1987 Apr 16;316:977-84 [2882420]

Parisi AF, Khuri S, Deupree RH, Sharma GV, Scott SM, Luchi RJ Medical compared with surgical management of unstable angina. 5-year mortality and morbidity in the Veterans Administration Study. *Circulation* 1989 Nov;80:1176-89 [2680157]

Scott SM, Deupree RH, Sharma GV, Luchi RJ VA Study of Unstable Angina. 10-year results show duration of surgical advantage for patients with impaired ejection fraction. *Circulation* 1994 Nov;90:III20-3 [7955237]

Sharma GV, Deupree RH, Khuri SF, Parisi AF, Luchi RJ, Scott SM Coronary bypass surgery improves survival in high-risk unstable angina. Results of a Veterans Administration Cooperative study with an 8-year follow-up. Veterans Administration Unstable Angina Cooperative Study Group. *Circulation* 1991 Nov;84:III260-7 [1934418]

## **10 DVT prophylaxis**

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>Suloctidil vs placebo</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<a href="#">Turpie , 1985</a> n=68/68	Suloctidil versus Placebo	-	double-blind

More details and results :

- antithrombotics for DVT prophylaxis in general surgery at <http://www.trialresultscenter.org/go-Q92>
- antiplatelets drug for DVT prophylaxis in general surgery at <http://www.trialresultscenter.org/go-Q461>
- antiplatelets drug for DVT prophylaxis in all type of patients at <http://www.trialresultscenter.org/go-Q462>

## References

### Turpie, 1985:

Turpie AG, Gent M, Doyle DJ, Saerens E, de Boer AC, Talbot C, McNamee J, Hirsh J An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. *Thromb Res* 1985;39:173-81 [[2992116](#)]

20

## 11 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>premixed insulin lispro vs basal-bolus</b>			
<a href="#">Masuda , 2008</a> n=NA follow-up:	twice-daily 50/50 premixed insulin lispro versus NPH insulin at bedtime and preprandial insulin lispro	insulin-naive type 2 diabetic patients	
<b>morning insulin glargine vs bedtime insulin glargine</b>			
<a href="#">Fritche</a> n=463/232 follow-up: 24 weeks	morning insulin glargine versus bedtime insulin glargine	patients with type 2 diabetes previously treated with oral antidiabetic agents	open
<b>insulin vs control</b>			
<a href="#">UGDP</a> n=414/205 follow-up:	-	-	
<a href="#">UKPDS 33</a> n=911/896 follow-up:	-	-	

continued...

Trial	Treatments	Patients	Trials design and methods
<b>insulin glargine vs control</b>			
<b>ORIGINE , 2012</b> [NCT00069784] n=6264/6273 follow-up: 6.2 years	insulin glargine (with a target fasting blood glucose level of 95 mg per deciliter versus standard care	with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	
<b>insulin detemir vs glargine</b>			
<b>Fadini , 2011</b> n=NA	-	-	
<b>insulin glulisine + glargine vs glargine once daily</b>			
<b>Owens , 2011</b> n=49/57 follow-up: 3 months	basal+bolus (single dose of insulin glulisine immediately prior to the main meal) versus basal insulin (glargin)	patients with T2DM using any basal insulin and HbA1c >7.0% after 3-month of insulin glargine titrated to optimize fasting bloodglucose control	Parallel groups open-label US, UK, Russia
<b>insulin lispro protamine suspension plus lispro vs glargine plus lispro</b>			
<b>Koivisto , 2011</b> n=NA	-	-	
<b>repaglinide + insulin vs insulin</b>			
<b>AGEE-1524</b> [NCT00799448] n=NA follow-up:	repaglinide combined with insulin NPH versus biphasic human insulin 30 alone	type 2 diabetics inadequately controlled with sulfonylurea (SU) +/- biguanide therapy	open Greece
<b>AGEE-3020</b> n=NA	-	-	
<b>biphasic insulin aspart 30 vs insulin detemir</b>			
<b>Lundby , 2009</b> n=NA follow-up:	biphasic insulin aspart 30 versus insulin detemir before bedtime	-	
<b>pioglitazone + sulfonylurea vs metformin + sulfonylurea</b>			
<b>EC409</b> n=319/320 follow-up: 104 wk	Pioglitazone + sulfonylurea versus Metformin + sulfonylurea	patients with type 2 diabetes	Parallel groups
<b>insulin detemir vs NPH insulin</b>			
<b>Hermansen</b> n=236/237 follow-up: 26 weeks	insulin detemir twice-daily versus NPH insulin	insulin-naive people with type 2 diabetes	
<b>lispro insulin vs NPH insulin</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>Bastyr , 2000</b> n=NA follow-up:	insulin lispro versus bedtime NPH insulin	-	
<b>insulin aspart at mealtimes vs NPH insulin once daily</b>			
<b>Gram , 2011</b> n=NA follow-up:	insulin aspart at mealtimes versus NPH insulin once daily at bedtime	-	
<b>insulin glargine vs placebo</b>			
<b>GRACE - ORIGIN (glargine) , 2012</b> n=1184 follow-up:	insulin glargine (with a target fasting blood glucose level of $\leq 95$ mg per deciliter [5.3 mmol per liter]) versus standard glycemic care alone	subject with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	Factorial plan open-label
<b>n-3 fatty acid supplement vs placebo</b>			
<b>GRACE - ORIGIN (n-3 fatty acid)</b> n=1184 follow-up: 4.9y (median)	n-3 fatty acid supplement versus placebo	subjects with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	Factorial plan double-blind
<b>sulfinyrazone vs placebo</b>			
<b>Dutch , 1980 <i>unpublished</i></b> n=30/31 follow-up: 32 months	-	-	Parallel groups
<b>pioglitazone + insulin vs placebo (add on insulin)</b>			
<b>OPI-502</b> n=110/112 follow-up: 20 wk	Pioglitazone + insulin versus Placebo + insulin	Insulin-dependent DM-2	Parallel groups
<b>PNFP-014</b> n=379/187 follow-up: 16 wk	Pioglitazone insulin versus Placebo + insulin	patients with type 2 diabetes	Parallel groups
<b>insulin glargine plus insulin glulisine vs premixed insulin analogues</b>			
<b>Levin , 2011</b> n=NA	-	-	
<b>lispro insulin + NPH insulin vs regular insulin + NPH insulin</b>			
<b>Altuntas , 2003</b> n=NA follow-up:	lispro insulin + NPH insulin versus regular insulin + NPH insulin	-	
<b>lispro twice daily + NPH insulin vs regular insulin + NPH insulin</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
Vignati n=NA follow-up:	twice-daily insulin lispro in combination with NPH human insulin versus regular human insulin in combination with NPH human insulin	-	
<b>SU vs rosiglitazone (add on MET)</b>			
Hamann , 2008 n=NA follow-up: 52 weeks	combination sulphonylurea plus metformin versus rosiglitazone/metformin fixed-dose combination	overweight individuals with inadequately controlled type 2 diabetes mellitus. Individuals with inadequate glycaemic control (HbA (1c) >or =7% ) while on metformin monotherapy (>or =0.85 g/day)	
<b>pioglitazone + sulfonylurea vs sulfonylurea</b>			
PNFP-010 n=373/187 follow-up: 16 wk	Pioglitazone + sulfonylurea versus Sulfonylurea	patients with type 2 diabetes	Parallel groups
<b>more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie</b>			
ABCD target (H) , 2000 n=237/233 follow-up: 5 year	intensive treatment with a diastolic blood pressure goal of 75 mmHg versus moderate treatment with a diastolic blood pressure goal of 80-89 mmHg	diabetes patients with DBP >=90 mmHg	Parallel groups open
ABCD target (N) , 2002 n=237/243 follow-up:	intensive treatment (diastolic blood pressure decrease of 10 mmHg below baseline DBP) versus moderate treatment (diastolic blood pressure goal of 80-89 mmHg)	diabetes patients with diastolic blood pressure between 80 and 89mmHg	Parallel groups open

More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q81>
- anti hypertensive agents for diabetes type 2 in patients with hypertension at <http://www.trialresultscenter.org/go-Q83>
- antiplatelets drug for diabetes type 2 in patients without cardiovascular disease at <http://www.trialresultscenter.org/go-Q221>
- insulin sensitizers - glitazones for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q321>
- prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q341>
- antiplatelets drug for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q362>

- insulin sensitizer for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q377>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- prevention for diabetes type 2 in people with impaired glucose tolerance at <http://www.trialresultscenter.org/go-Q416>
- intensive therapy for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q459>
- insulin secretagogues - sulfonylureas for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q483>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>
- insulin therapy for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q548>
- insulin secretagogues - Meglitinides (glinides) for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q549>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>
- glucose lowering for cardiovascular prevention for diabetes type 2 in meta-regression at <http://www.trialresultscenter.org/go-Q692>

## References

### Masuda, 2008:

Masuda H, Sakamoto M, Irie J, Kitaoka A, Shiono K, Inoue G, Atsuda K, Yamada S, Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients. *Diabetes Obes Metab* 2008;10:1261-5. [18494811] [10.1111/j.1463-1326.2008.00897.x](https://doi.org/10.1111/j.1463-1326.2008.00897.x)

### Fritsche , :

Fritsche A, Schweitzer MA, Hring HU Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. *Ann Intern Med* 2003;138:952-9 [12809451]

### UGDP, :

Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. *Diabetes* 1982 Nov;31 Suppl 5:1-81 [6757026]

### UKPDS 33, :

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998 Sep 12;352:837-53 [9742976]

### ORIGINE, 2012:

Gerstein HC, Bosch J, Dagenais GR, Daz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydn LE, Yusuf S Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med* 2012;367:319-28 [22686416]

### Fadini, 2011:



Fadini GP, de Kreutzenberg SV, Mariano V, Boscaro E, Bertolini F, Mancuso P, Quarna J, Marescotti M, Agostini C, Tiengo A, Avogaro A, Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. *Diabetes Obes Metab* 2011;13:718-25. [21410861] [10.1111/j.1463-1326.2011.01396.x](https://doi.org/10.1111/j.1463-1326.2011.01396.x)

**Owens, 2011:**

Owens DR, Luzio SD, Sert-Langeron C, Riddle MC Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. *Diabetes Obes Metab* 2011;13:1020-7 [21679291] [10.1111/j.1463-1326.2011.01459.x](https://doi.org/10.1111/j.1463-1326.2011.01459.x)

**Koivisto, 2011:**

Koivisto V, Cleall S, Pontiroli AE, Giugliano D, Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. *Diabetes Obes Metab* 2011;13:1149-57. [21819517] [10.1111/j.1463-1326.2011.01484.x](https://doi.org/10.1111/j.1463-1326.2011.01484.x)

**AGEE-1524, 0:**

**AGEE-3020, :**

**Lundby, 2009:**

Lundby Christensen L, Almdal T, Boesgaard T, Breum L, Dunn E, Gade-Rasmussen B, Gluud C, Hedetoft C, Jarloev A, Jensen T, Krarup T, Johansen LB, Lund SS, Madsbad S, Mathiesen E, Moelvig J, Nielsen F, Perrild H, Pedersen O, Roeder M, Sneppen SB, Snorgaard Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. *Diabetes Obes Metab* 2009;11:315-22. [19267709] [10.1111/j.1463-1326.2008.00959.x](https://doi.org/10.1111/j.1463-1326.2008.00959.x)

**EC409, :**

**Hermansen , :**

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetes Care* 2006;29:1269-74 [16732007] [10.2337/dc05-1365](https://doi.org/10.2337/dc05-1365)

**Bastyr, 2000:**

Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE, Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. *Diabetes Care* 2000;23:1236-41. [10977012]

**Gram, 2011:**

Gram J, Henriksen JE, Grodum E, Juhl H, Hansen TB, Christiansen C, Yderstrde K, Gjessing H, Hansen HM, Vestergaard V, Hangaard J, Beck-Nielsen H, Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. *Diabetes Care* 2011;34:27-33. [20929990] [10.2337/dc10-0531](https://doi.org/10.2337/dc10-0531)

**GRACE - ORIGIN (glargine), 2012:**

**GRACE - ORIGIN (n-3 fatty acid), :**

**Dutch, 1980:**

unpublished

Pannebakker M, Jonker JJC, Den Ottolander GJH. Proceedings of VI International Congress of Mediterranean League Against Thrombosis 1980:Abstract 167

**OPI-502, :**

**PNFP-014, :**

**Levin, 2011:**

Levin PA, Zhang Q, Mersey JH, Lee FY, Bromberger LA, Bhushan M, Bhushan R, Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. *Clin Ther* 2011;33:841-50. [21719107] [10.1016/j.clinthera.2011.05.091](https://doi.org/10.1016/j.clinthera.2011.05.091)

**Altuntas, 2003:**

Altuntas Y, Ozen B, Ozturk B, Sengul A, Ucak S, Ersoy O, Karul S, Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. *Diabetes Obes Metab* 2003;5:371-8. [[14617222](#)]

**Vignati, 0:**

Vignati L, Anderson JH, Iversen PW, Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. *Clin Ther* ;19:1408-21. [[9444449](#)]

**Hamann, 2008:**

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. *Exp Clin Endocrinol Diabetes* 2008;116:6-13 [[18095238](#)] [10.1055/s-2007-984441](#)

**PNFP-010, :****ABCD target (H) , 2000:**

Estacio RO, Jeffers BW, Gifford N, Schrier RW Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. *Diabetes Care* 2000;23 Suppl 2:B54-64 [[10860192](#)]

**ABCD target (N) , 2002:**

Schrier RW, Estacio RO, Esler A, Mehler P Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kidney Int* 2002;61:1086-97 [[11849464](#)] [10.1046/j.1523-1755.2002.00213.x](#)

## 12 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
<b>subcutaneous heparin vs intravenous heparin</b>			
<a href="#">Krahenbuhl , 1979</a> n=23/25	subcutaneous sodic heparin 30 000 U daily (mean) versus intravenous sodic heparin 30 000 U daily (mean)	-	
<a href="#">Bentley , 1980</a> n=50/50	subcutaneous calcic heparin 37 000 U daily (mean) versus intravenous sodic heparin 36 800 U daily (mean)	-	
<a href="#">Andersson , 1982</a> n=72/69	subcutaneous sodic heparin 36 800 U daily (mean) versus intravenous sodic heparin 33 250 U daily (mean)	-	

continued...

Trial	Treatments	Patients	Trials design and methods
Hull , 1986 n=57/58	subcutaneous sodic heparin 32 300 U daily (mean) versus intravenous sodic heparin 29 700 U daily (mean)	-	
Doyle , 1987 n=51/52	subcutaneous calcic heparin 29 200 U daily (mean) versus intravenous calcic heparin 29 600 U daily (mean)	-	
Walker , 1987 n=50/50	subcutaneous calcic heparin 29 375 U daily (mean) versus intravenous calcic heparin 24 384 U daily (mean)	-	
Lopaciuk , 3000 n=48/46	subcutaneous sodic heparin 34 400 U daily (mean) versus intravenous sodic heparin 37 000 U daily (mean)	-	
Pini , 1990 n=138/133	subcutaneous calcic heparin 33 800 U daily (mean) versus intravenous sodic heparin 31 700 U daily (mean)	-	

More details and results :

- antithrombotics for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q101>
- heparin (UFH or LMWH) for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q204>
- UFH for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q205>

## References

### Krahenbuhl, 1979:

Krahenbuhl B, Simon CA, Bouvier CA, Schinas P, Hopf MA, Cochet B [Heparin treatment. Comparison between intravenous and subcutaneous administration] Schweiz Med Wochenschr 1979;109:1322-5 [504973]

### Bentley, 1980:

Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones N An objective study of alternative methods of heparin administration. *Thromb Res* 1980;18:177-87 [7404497]

**Andersson, 1982:**

Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist S Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis. *Thromb Res* 1982;27:631-9 [7179208]

**Hull, 1986:**

Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. *N Engl J Med* 1986;315:1109-14 [3531862]

**Doyle, 1987:**

Doyle DJ, Turpie AG, Hirsh J, Best C, Kinch D, Levine MN, Gent M Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. *Ann Intern Med* 1987;107:441-5 [3307582]

**Walker, 1987:**

Walker MG, Shaw JW, Thomson GJ, Cumming JG, Thomas ML Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial. *Br Med J (Clin Res Ed)* 1987;294:1189-92 [3109574]

**Lopaciuk, 3000:**

**Pini, 1990:**

Pini M, Pattachini C, Quintavalla R, Poli T, Megha A, Tagliaferri A, Manotti C, Dettori AG Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis—a randomized clinical trial. *Thromb Haemost* 1990;64:222-6 [2270531]

28

## 13 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
<b>CABG+surgical ventricular reconstruction vs CABG</b>			
STICH (ventricular reconstruction) , 2009 [NCT00023595] n=501/499 follow-up: 48 months	CABG with surgical ventricular reconstruction versus CABG	patients with anterior-apical regional left ventricular dysfunction	Parallel groups open

More details and results :

- myocardial revascularization for coronary artery disease in all type of patient at <http://www.trialresultscenter.org/go-Q26>

### References

**STICH (ventricular reconstruction), 2009:**

Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009 Apr 23;360:1705-17 [19329820] 10.1056/NEJMoa0900559

Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JL STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol 2010;56:490-8 [20670760] 10.1016/j.jacc.2009.11.102

## 14 CABG surgery

Trial	Treatments	Patients	Trials design and methods
<b>sulotroban vs control</b>			
German sulotroban , 1989 n=90/85 follow-up: 21d	-	-	
<b>sulfinpyrazone vs placebo</b>			
Baur , 1982 n=130/125 follow-up: 10d	sulfinpyrazone 800 mg/day versus placebo	patients undergoing CABG	double blind

29

More details and results :

- antiplatelets drug for CABG surgery in all type of patients at <http://www.trialresultscenter.org/go-Q225>

## References

### German sulotroban, 1989:

Hacker RW, Troka M, Yukseltan I, Pohlmann V, Meier P, Zimmermann T, et al. Reduction of the vein graft occlusion rate after coronary artery bypass surgery by treatment with a thromboxane receptor antagonist. Z Kardiol 1989;78(suppl 3):48-9

### Baur, 1982:

Baur HR, VanTassel RA, Pierach CA, Gobel FL Effects of sulfinpyrazone on early graft closure after myocardial revascularization. Am J Cardiol 1982;49:420-4 [7058755]

## 15 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
<b>suloctidil vs placebo</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
Adriaensen , 1976 n=15/15 follow-up: 2 months	Suloctidil 200 mg / j versus Placebo	patients suffering from intermittent claudication ( stade II)	Parallel groups double blind
Verhaeghe , 1981 n=NA follow-up: 6 months	Suloctidil 200 mg / j versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
Jones , 1982 n=18/22 follow-up: 6 months	Suloctidil 300 mg / j versus Placebo	patients suffering from intermittent claudication (stade II)	Parallel groups double blind
Holm , 1984 n=20/20 follow-up: 2.75 y	Suloctidil 300 mg / j versus Placebo	AOMI stade II	Parallel groups double blind

More details and results :

- antiplatelets drug for peripheral vascular diseases in all type of patient at <http://www.trialresultscenter.org/go-Q278>

## References

### Adriaensen, 1976:

Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo. Adriaensen H Curr Med Res Opin 1976;4:395-401 [793778]

### Verhaeghe, 1981:

Controlled trial of suloctidil in intermittent claudication. Verhaeghe R, Van Hoof A, Beyens G J Cardiovasc Pharmacol 1981 Mar-Apr;3:279-86 [6166799]

### Jones, 1982:

A double-blind trial of suloctidil v. placebo in intermittent claudication. Jones NA, De Haas H, Zahavi J, Kakkar VV Br J Surg 1982 Jan;69:38-40 [6274471]

### Holm, 1984:

Intermittent claudication: Suloctidil v.s. placebo treatment. Holm J, Lindblad L, Schersten T, Suurkula M Vasa 1984;13:175-8 [6331019]

Entry terms: aspirin, bivalirudin, Hirulog-1 Hirulog Angiomax, heparin, Heparin, Unfractionated Heparin, Heparinic Acid, Liquaemin, Sodium Heparin, Heparin Sodium, alpha-Heparin, alpha Heparin, , pioglitazone, Actos, prasugrel, prasugrel, CS 747, CS-747, LY 640315, LY640315, LY-640315, Effient, Efiend, rosuvastatin, Crestor, sulfapyrazone, suloctidil, sulotroban, trimetazidine, Centrophne, Vastarel, Idaptan, Trintazidine Irex, Vasartel, Trimetazidine Dihydrochloride,